Laura M. Spring
Harvard University · 467 works · 7,261 citations · h-index 36
Top works
- Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis
- Impact of pass/fail grading on medical students’ well‐being and academic outcomes
- Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer
- Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future
- Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer
- Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models
- ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer
- Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations
- Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab
- CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions
- Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer
- Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2− breast cancer: a randomized phase 3 trial
- Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions.
- Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
- HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial.
- Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker
- Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience
- Mechanisms of Resistance to Antibody–Drug Conjugates
- Metaplastic breast cancer: A review
- Stevens-Johnson syndrome–like eruption from palbociclib in a patient with metastatic breast cancer